Market Research Report: Imvax, Inc.

Company Overview

• Name: Imvax, Inc.

• Mission: Imvax is united behind a new approach to personalized immunotherapy with a strategy to deliver a portfolio of therapies targeting solid tumors.

• Founded: No information is available.

• Founders: David W. Andrews, M.D. (Co-Founder, Chief Medical Officer)

• Key People:

• John P. Furey (Chief Executive Officer)

• David W. Andrews, M.D. (Co-Founder, Chief Medical Officer)

• Mark A. Exley, Ph.D. (Chief Scientific Officer)

• Sean P. Hemingway (Chief Operating Officer)

• John M. Limongelli (Chief Legal Officer)

• Diana Martine (Head of Human Resources)

• Josh Muntner (Chief Financial Officer)

• Headquarters: 601 Walnut Street, Suite 440W, Philadelphia, PA 19106

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Imvax is known for developing personalized, whole tumor-derived immunotherapies, particularly focused on combatting solid tumors through its unique Goldspire™ immunotherapy platform.

Products

1. IGV-001

• Product Description: IGV-001 is an autologous biologic-device combination product derived from Imvax’s proprietary Goldspire™ immuno-oncology platform. It is designed to induce a broad and durable immune response against tumors, particularly targeting newly diagnosed glioblastoma (ndGBM).

• Key Features:

• Utilizes whole tumor-derived cells with an antisense oligonucleotide to stimulate immune response.

• Proven safety and tolerability in Phase 1 studies.

• Fast Track designation by the U.S. FDA for treatment of ndGBM.

• Efficacy signals include significant improvements in progression-free survival (PFS) and overall survival (OS).

2. Pipeline Products

• IEC-001: Targeting Endometrial Cancer (IND-enabling).

• IHC-001: Aimed at Hepatocellular Carcinoma (IND-enabling).

• IUC-001: Developed for Urothelial Cancer (IND-enabling).

• IOC-001: Focused on Ovarian Cancer (IND-enabling).

Recent Developments

Clinical Trials & Research

• Phase 2b Clinical Trial of IGV-001:

• Status: Enrollment completed in May 2024.

• Trial Details: Randomized, multicenter, double-blind, placebo-controlled trial on ndGBM patients.

• Design: Involves approximately 100 patients across 20 U.S. sites. Participants receive IGV-001 post-surgical resection or a placebo.

• Endpoints: Primary endpoint is Progression-Free Survival (PFS). Secondary endpoints include Overall Survival (OS) and safety.

• Fast Track Designation: Granted by FDA, allowing for expedited communication and review processes.

Financial Developments

• Financing: Successfully completed a $35 million financing round in 2024. Funds aimed to support operations and trial completion through mid-2025. Over 15 months, $57 million was raised, half from new investors.

Presentations & Data Disclosure

• SNO Annual Meeting (November 2023):

• Presented new data on IGV-001's Phase 1b study.

• Additionally, provided updates on Phase 2b clinical trials for IGV-001.

• Highlighted independent support from established neurosurgical oncology professionals.

Strategic Goals & Initiatives

• Imvax aims to pioneer advances in the treatment of glioblastoma, offering innovative solutions to areas of significant unmet need in the oncological landscape.

• Leverage Fast Track designation to expedite development and potential market entry of IGV-001.

• Continue investment in pipeline products and strategic partnerships to broaden its immunotherapy impact across other cancer types.

Partnerships

• No specific new partnerships have been mentioned in the data provided.

By consolidating its focus on personalized immunotherapies and leveraging strategic clinical advancements, Imvax continues to position itself as a notable player in the biopharmaceutical industry targeting solid tumors.